Research explained
DSIP + Ipamorelin: Sleep Evidence
DSIP and ipamorelin are sometimes promoted together as a sleep stack. The key evidence question is whether the combination itself has been tested. Separate studies of sleep and hormone release do not establish that combining the compounds improves sleep or recovery.
By PurePeptideHub Research Team · Evidence updated
Editorial evidence update; independent clinical review pending. Editorial standards
The sources below do not test DSIP plus ipamorelin as a combination. They do not establish a stack dose, schedule, or demonstrated synergy.
Evidence at a glance
Selected sources supporting this update. This is an editorial evidence summary, not a systematic review of every publication.
| Source and design | What it supports | What it cannot establish |
|---|---|---|
| Bes et al. — DSIP and insomnia (1992) Double-blind, matched-pairs study in 16 people with chronic insomnia. | Small objective effects and no improvement in subjective sleep quality; authors questioned major short-term benefit. | Small, short study of DSIP alone. |
| Gobburu et al. — ipamorelin in volunteers (1999) Intravenous dose-escalation pharmacology study in healthy men. | Characterized ipamorelin exposure and growth-hormone responses. | Not a sleep-treatment or combination trial. |
| FDA compounding safety concerns Regulatory safety information. | FDA identifies safety-data gaps for DSIP and ipamorelin. | Separate-compound data cannot establish combination safety. |
What the sleep study contributes
The DSIP study provides a human sleep reference, but its small sample and brief observation period limit confidence. Its findings do not justify a promise of deeper sleep for every user. A summary should report the weak and subjective results alongside any favorable objective measurement.
What the ipamorelin study does not measure
The volunteer study investigated drug exposure and growth-hormone response. It did not test whether adding ipamorelin to DSIP improves insomnia, sleep architecture, daytime function, or recovery. A hormone response is not a substitute for measuring those outcomes.
What would count as combination evidence
A useful combination study would identify the exact substances and formulations, compare the combination with an appropriate control, and ideally distinguish each component from their joint effect. It would also define sleep outcomes, collect adverse events, and allow enough follow-up. Without those comparisons, a claim of synergy is a hypothesis.
| Claim | Missing comparison |
|---|---|
| The stack works better than DSIP | Combination versus DSIP alone. |
| It improves sleep rather than only hormones | Validated sleep and daytime-function outcomes. |
| The stack is well tolerated | Systematic safety assessment of the combination. |
A practical way to read stack advice
Follow each citation to the original paper and check whether both compounds appear in the actual intervention. If one link is an insomnia study and another is a hormone study, the combination claim remains untested by those sources. This page intentionally offers no injection, dose-escalation, or cycling instructions.
Sources: FDA compounding safety concerns
Common questions
Does DSIP plus ipamorelin have proven synergy?
Not in the studies reviewed here. Demonstrating an effect for one component is not the same as demonstrating a beneficial interaction.
Does more growth hormone prove better sleep?
No. A trial needs to measure sleep and relevant patient outcomes directly.
Why is there no stack schedule on this page?
The cited evidence does not establish a validated schedule for this combination. Presenting one would imply stronger clinical support than these sources provide.
Continue your research
Educational information only. This page does not recommend a medicine, dose or injection protocol. Report a correction with its source.